Dnaprint Genomics Stock Net Income
DNAPrint Genomics fundamentals help investors to digest information that contributes to DNAPrint Genomics' financial success or failures. It also enables traders to predict the movement of DNAPrint Stock. The fundamental analysis module provides a way to measure DNAPrint Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DNAPrint Genomics stock.
DNAPrint |
DNAPrint Genomics Company Net Income Analysis
DNAPrint Genomics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current DNAPrint Genomics Net Income | (12.35 M) |
Most of DNAPrint Genomics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DNAPrint Genomics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, DNAPrint Genomics reported net income of (12.35 Million). This is much lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is notably higher than that of the company.
DNAPrint Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DNAPrint Genomics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DNAPrint Genomics could also be used in its relative valuation, which is a method of valuing DNAPrint Genomics by comparing valuation metrics of similar companies.DNAPrint Genomics is currently under evaluation in net income category among its peers.
DNAPrint Fundamentals
| Return On Asset | -1.05 | |||
| Profit Margin | (2.36) % | |||
| Operating Margin | (7.31) % | |||
| Current Valuation | 5.21 M | |||
| Shares Outstanding | 644.61 M | |||
| Shares Owned By Institutions | 0.18 % | |||
| Price To Sales | 0.0003 X | |||
| Revenue | 2.43 M | |||
| Gross Profit | 754.07 K | |||
| EBITDA | (5.78 M) | |||
| Net Income | (12.35 M) | |||
| Cash And Equivalents | 134.35 K | |||
| Total Debt | 240 K | |||
| Current Ratio | 0.17 X | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (5.78 M) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 24 | |||
| Beta | 23.48 | |||
| Market Capitalization | 644 | |||
| Total Asset | 10.27 M | |||
| Retained Earnings | (45.53 M) | |||
| Working Capital | (9.35 M) | |||
| Current Asset | 1.89 M | |||
| Current Liabilities | 11.24 M | |||
| Net Asset | 10.27 M |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in DNAPrint Stock
If you are still planning to invest in DNAPrint Genomics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the DNAPrint Genomics' history and understand the potential risks before investing.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |